Skip to main content
. Author manuscript; available in PMC: 2015 Sep 21.
Published in final edited form as: Analyst. 2014 Sep 21;139(18):4401–4410. doi: 10.1039/c4an00990h

Fig. 2.

Fig. 2

Clinically approved contrast agents: GdIII-containing diethylenetriaminepentaacetate (DTPA), 1; GdIII-containing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA), 2; GdIII-containing α-(benzyloxymethyl)diethylenetriaminepenta-acetate (BOPTA), 3; GdIII-DOTA derivative 4; and GdIII-DTPA derivatives 5 and 6 (coordinated water molecules and counter ions are not shown for clarity).